Regeneron Pharmaceuticals (REGN) Stock News

Regeneron will present 10 abstracts at ESMO 2026, including late-breaking overall survival data from the C-POST Phase 3 trial of adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma and Phase 2 sub-analyses of factor XI antibodies cenvacibart and amrecibart for cancer-associated thrombosis. The presentations also cover neoadjuvant Libtayo in CSCC, fianlimab plus cemiplimab in advanced melanoma, cemiplimab in NSCLC, and ubamatamab in ovarian cancer.

Regeneron's ubamatamab achieved a 73% objective response rate in 11 patients with advanced low-grade serous ovarian cancer at the 800 mg dose. Median duration of response was 9 months and median progression-free survival was 11 months. The company is enrolling a registrational trial and planning a confirmatory Phase 3 study.

Regeneron and Sanofi expanded their antibody collaboration with four new long-acting immunology antibodies. Regeneron receives $1 billion upfront and up to $7 billion in milestones. The companies will split development costs and profits 50:50 globally.

Regeneron grants 10-year performance share units to CEO and CSO.